Details for New Drug Application (NDA): 075877
✉ Email this page to a colleague
NDA 075877 describes TERBUTALINE SULFATE, which is a drug marketed by Areva Pharms, Chartwell Injectable, Dr Reddys, Epic Pharma Llc, Fresenius Kabi Usa, Hikma Farmaceutica, Impax Labs, Lannett Co Inc, and Twi Pharms, and is included in nine NDAs. It is available from eleven suppliers. Additional details are available on the TERBUTALINE SULFATE profile page.
The generic ingredient in TERBUTALINE SULFATE is terbutaline sulfate. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the terbutaline sulfate profile page.
The generic ingredient in TERBUTALINE SULFATE is terbutaline sulfate. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the terbutaline sulfate profile page.
Summary for 075877
| Tradename: | TERBUTALINE SULFATE |
| Applicant: | Impax Labs |
| Ingredient: | terbutaline sulfate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 075877
Suppliers and Packaging for NDA: 075877
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TERBUTALINE SULFATE | terbutaline sulfate | TABLET;ORAL | 075877 | ANDA | Amneal Pharmaceuticals of New York LLC | 0115-2611 | 0115-2611-01 | 100 TABLET in 1 BOTTLE (0115-2611-01) |
| TERBUTALINE SULFATE | terbutaline sulfate | TABLET;ORAL | 075877 | ANDA | Amneal Pharmaceuticals of New York LLC | 0115-2611 | 0115-2611-02 | 500 TABLET in 1 BOTTLE (0115-2611-02) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2.5MG | ||||
| Approval Date: | Jun 26, 2001 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Jun 26, 2001 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
